Cullinan Therapeutics

NSQ:CGEM · US2300311063

BiotechnologySmall

360° View

Value17

Price/Sales56

Price/Earnings49

Price/Book38

Dividend Yield1

Growth25

Revenue Growth—

Profit Growth26

Capital Growth24

TSR 52w48

Safety90

Leverage89

Liquidity59

Refinancing45

Combined34

Sentiment95

Analyst Opinions85

Pro Holdings83

Opinion Changes50

Market Pulse78

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGS

Founded2016

Employees109

Websitecullinantherapeutics.com

ISINUS2300311063

Last UpdateApr 2, 2026

Index & Theme

HematologyRheumatologyImmunologyOncologyChronic DiseasesBiopharmaBiotechnologyMedical Device

Description

Cullinan Therapeutics, Inc. is a biopharmaceutical company. The company is developing potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer. The company pursues promising therapeutic targets while leveraging cor…

Analysis

Cullinan Therapeutics's 360° View rank of 61 places it above its peer average — better than 61% of its true peers.

It's lagging on growth (25) and expensive versus peers (17). On safety it is very well financed (90), and the market shows strongly positive sentiment (95). Taken together, its Combined rank of 34 reads as below its peer average.

360° rank · history

1007550250

2026

All-time high

Jun 2026

All-time low

Mar 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Cullinan Therapeutics with its peers

Greenwich Lifesciences

NAQ:GLSI

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Vor Biopharma

NSQ:VOR

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Zymeworks

NSQ:ZYME

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Vir Biotechnology

NSQ:VIR

CountryUSA

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

Kodiak Sciences

NMQ:KOD

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Spyre Therapeutics

NSQ:SYRE

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →